39. Tuberculosis drug resistance and susceptibility testing in a nutshell
Saturday, 05 December 2015, 12:30-13:30

Chair: Amy PIATEK (USA)
Track: Drug resistance determination - molecular and phenotypic

PC-1025-05  Determinants of pulmonary tuberculosis among women in Afghanistan
Sd Mahmoodi, M Seddiq, Mr Aloudal, M Mashal, S Sardar Mohammad, Ghul Qader (Afghanistan)

PC-1026-05  Evaluation of the BACTEC MGIT 960 system for bedaquiline susceptibility testing of Mycobacterium tuberculosis
G Torrea, N Coeck, C Desmaretz, T Van De Parre, T Van Poucke, N Lounis, B C De Jong, L Rigouts (Belgium)

PC-1027-05  The potential impact of up-front drug susceptibility testing on India’s MDR-TB epidemic
Ks Sachdeva, N Raizada, A Sreenivas, C Denkinger, C Paramasivan, S Kulsange, C Boehme, N Arinaminpathy (India, Switzerland, UK)

PC-1028-05  Linezolid susceptibility of XDR-TB strains from Pakistan tested on the MGIT 960 system
J Farooqi, K Jabeen, S Shafiq, R Hasan (Pakistan)

PC-1029-05  Comparison of the MDR/XDR-TB Colour Test, Xpert® MTB/RIF, and MODS assays to diagnose rifampicin-resistant TB
M Tovar, E Ramos, T Valencia, S Datta, R Montoya, R Montoya, Tom Wingfield, A Valencia, R Patrocinio, C Evans (Peru, UK)

PC-1030-05  Exploring drug resistant tuberculosis profiles in the West Coast region of the Western Cape Province, South Africa
P Tshavhungwe, R M Warren, M Buckley, T Dolby, P Van Helden, J Simpson, K Jacobson, E Streicher (South Africa, USA)

PC-1031-05  Direct comparison of spontaneously expectorated sputum with sputum expectorated following mouth wash with water or with chlorhexidine
C Kleinhans, M Hanekom, S Friedrich, A Venter, A Diacon (South Africa)

PC-1032-05  Molecular testing for tuberculosis in the United States: implications for national surveillance
L Armstrong, T Dalton, R Oatis, J Higashi, S Allen, M Pecha, A Starks (USA)